Melatonin in sleep disorders
Date
2022-09Permanent link
https://hdl.handle.net/11351/8434DOI
10.1016/j.nrleng.2018.08.004
ISSN
2173-5808
PMID
36064286
Abstract
Melatonin is the main hormone involved in the control of the sleep-wake cycle. It is easily synthesisable and can be administered orally, which has led to interest in its use as a treatment for insomnia. Moreover, as production of the hormone decreases with age, in inverse correlation with the frequency of poor sleep quality, it has been suggested that melatonin deficit is at least partly responsible for sleep disorders. Treating this age-related deficit would therefore appear to be a natural way of restoring sleep quality, which is lost as patients age. However, despite the undeniable theoretical appeal of this approach to insomnia, little scientific evidence is available that supports any benefit of this substitutive therapy. Furthermore, the most suitable dose ranges and pharmaceutical preparations for melatonin administration are yet to be clearly defined. This review addresses the physiology of melatonin, the different pharmaceutical preparations, and data on its clinical usefulness.
Keywords
Melatonin; Circadian rhythm; Primary insomniaBibliographic citation
Poza JJ, Pujol M, Ortega-Albás JJ, Romero O. Melatonin in sleep disorders. Neurologia (Engl Ed). 2022 Sep;37(7):575–85.
Audience
Professionals
This item appears in following collections
- HVH - Articles científics [4471]
The following license files are associated with this item:




